-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on RxSight, Lowers Price Target to $8

Benzinga·11/04/2026 17:18:57
Listen to the news
Piper Sandler analyst Adam Maeder maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $10 to $8.